240 related articles for article (PubMed ID: 22250853)
1. Onset of alcohol or substance use disorders following treatment for adolescent depression.
Curry J; Silva S; Rohde P; Ginsburg G; Kennard B; Kratochvil C; Simons A; Kirchner J; May D; Mayes T; Feeny N; Albano AM; Lavanier S; Reinecke M; Jacobs R; Becker-Weidman E; Weller E; Emslie G; Walkup J; Kastelic E; Burns B; Wells K; March J
J Consult Clin Psychol; 2012 Apr; 80(2):299-312. PubMed ID: 22250853
[TBL] [Abstract][Full Text] [Related]
2. The Treatment for Adolescents with Depression Study (TADS): methods and message at 12 weeks.
March J; Silva S; Vitiello B;
J Am Acad Child Adolesc Psychiatry; 2006 Dec; 45(12):1393-403. PubMed ID: 17135984
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of cognitive behavioral therapy/motivational enhancement therapy (CBT/MET) in a treatment trial of comorbid MDD/AUD adolescents.
Cornelius JR; Douaihy A; Bukstein OG; Daley DC; Wood SD; Kelly TM; Salloum IM
Addict Behav; 2011 Aug; 36(8):843-8. PubMed ID: 21530092
[TBL] [Abstract][Full Text] [Related]
4. Treatment response in depressed adolescents with and without co-morbid attention-deficit/hyperactivity disorder in the Treatment for Adolescents with Depression Study.
Kratochvil CJ; May DE; Silva SG; Madaan V; Puumala SE; Curry JF; Walkup J; Kepley H; Vitiello B; March JS
J Child Adolesc Psychopharmacol; 2009 Oct; 19(5):519-27. PubMed ID: 19877976
[TBL] [Abstract][Full Text] [Related]
5. Treatment for Adolescents with Depression Study (TADS): safety results.
Emslie G; Kratochvil C; Vitiello B; Silva S; Mayes T; McNulty S; Weller E; Waslick B; Casat C; Walkup J; Pathak S; Rohde P; Posner K; March J; ;
J Am Acad Child Adolesc Psychiatry; 2006 Dec; 45(12):1440-55. PubMed ID: 17135989
[TBL] [Abstract][Full Text] [Related]
6. Remission and residual symptoms after short-term treatment in the Treatment of Adolescents with Depression Study (TADS).
Kennard B; Silva S; Vitiello B; Curry J; Kratochvil C; Simons A; Hughes J; Feeny N; Weller E; Sweeney M; Reinecke M; Pathak S; Ginsburg G; Emslie G; March J;
J Am Acad Child Adolesc Psychiatry; 2006 Dec; 45(12):1404-11. PubMed ID: 17135985
[TBL] [Abstract][Full Text] [Related]
7. Acute time to response in the Treatment for Adolescents with Depression Study (TADS).
Kratochvil C; Emslie G; Silva S; McNulty S; Walkup J; Curry J; Reinecke M; Vitiello B; Rohde P; Feeny N; Casat C; Pathak S; Weller E; May D; Mayes T; Robins M; March J;
J Am Acad Child Adolesc Psychiatry; 2006 Dec; 45(12):1412-8. PubMed ID: 17135986
[TBL] [Abstract][Full Text] [Related]
8. Mental health service use among adolescents following participation in a randomized clinical trial for depression.
Brenner SL; Burns BJ; Curry JF; Silva SG; Kratochvil CJ; Domino ME
J Clin Child Adolesc Psychol; 2015; 44(4):551-8. PubMed ID: 24661263
[TBL] [Abstract][Full Text] [Related]
9. Trajectories of Symptom Change in the Treatment for Adolescents With Depression Study.
Scott K; Lewis CC; Marti CN
J Am Acad Child Adolesc Psychiatry; 2019 Mar; 58(3):319-328. PubMed ID: 30768414
[TBL] [Abstract][Full Text] [Related]
10. Double-blind placebo-controlled trial of fluoxetine in adolescents with comorbid major depression and an alcohol use disorder.
Cornelius JR; Bukstein OG; Wood DS; Kirisci L; Douaihy A; Clark DB
Addict Behav; 2009 Oct; 34(10):905-9. PubMed ID: 19321268
[TBL] [Abstract][Full Text] [Related]
11. A randomized controlled trial of fluoxetine and cognitive behavioral therapy in adolescents with major depression, behavior problems, and substance use disorders.
Riggs PD; Mikulich-Gilbertson SK; Davies RD; Lohman M; Klein C; Stover SK
Arch Pediatr Adolesc Med; 2007 Nov; 161(11):1026-34. PubMed ID: 17984403
[TBL] [Abstract][Full Text] [Related]
12. Achievement and maintenance of sustained response during the Treatment for Adolescents With Depression Study continuation and maintenance therapy.
Rohde P; Silva SG; Tonev ST; Kennard BD; Vitiello B; Kratochvil CJ; Reinecke MA; Curry JF; Simons AD; March JS
Arch Gen Psychiatry; 2008 Apr; 65(4):447-55. PubMed ID: 18391133
[TBL] [Abstract][Full Text] [Related]
13. Impact of childhood trauma on treatment outcome in the Treatment for Adolescents with Depression Study (TADS).
Lewis CC; Simons AD; Nguyen LJ; Murakami JL; Reid MW; Silva SG; March JS
J Am Acad Child Adolesc Psychiatry; 2010 Feb; 49(2):132-40. PubMed ID: 20215935
[TBL] [Abstract][Full Text] [Related]
14. Moderators and Predictors of Response After 36 Weeks of Treatment in the Treatment for Adolescents with Depression Study (TADS).
O'Dor SL; Washburn J; Howard KR; Reinecke MA
Res Child Adolesc Psychopathol; 2021 Nov; 49(11):1489-1501. PubMed ID: 34050856
[TBL] [Abstract][Full Text] [Related]
15. Predictors and moderators of acute outcome in the Treatment for Adolescents with Depression Study (TADS).
Curry J; Rohde P; Simons A; Silva S; Vitiello B; Kratochvil C; Reinecke M; Feeny N; Wells K; Pathak S; Weller E; Rosenberg D; Kennard B; Robins M; Ginsburg G; March J;
J Am Acad Child Adolesc Psychiatry; 2006 Dec; 45(12):1427-39. PubMed ID: 17135988
[TBL] [Abstract][Full Text] [Related]
16. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid substance use disorders.
Beaulieu S; Saury S; Sareen J; Tremblay J; Schütz CG; McIntyre RS; Schaffer A;
Ann Clin Psychiatry; 2012 Feb; 24(1):38-55. PubMed ID: 22303521
[TBL] [Abstract][Full Text] [Related]
17. Substance use disorder comorbidity in major depressive disorder: an exploratory analysis of the Sequenced Treatment Alternatives to Relieve Depression cohort.
Davis LL; Rush JA; Wisniewski SR; Rice K; Cassano P; Jewell ME; Biggs MM; Shores-Wilson K; Balasubramani GK; Husain MM; Quitkin FM; McGrath PJ
Compr Psychiatry; 2005; 46(2):81-9. PubMed ID: 15723023
[TBL] [Abstract][Full Text] [Related]
18. Estimating patient-specific treatment advantages in the 'Treatment for Adolescents with Depression Study'.
Foster S; Mohler-Kuo M; Tay L; Hothorn T; Seibold H
J Psychiatr Res; 2019 May; 112():61-70. PubMed ID: 30856378
[TBL] [Abstract][Full Text] [Related]
19. Comparative efficacy and durability of continuation phase cognitive therapy for preventing recurrent depression: design of a double-blinded, fluoxetine- and pill placebo-controlled, randomized trial with 2-year follow-up.
Jarrett RB; Thase ME
Contemp Clin Trials; 2010 Jul; 31(4):355-77. PubMed ID: 20451668
[TBL] [Abstract][Full Text] [Related]
20. Do comorbid social and other anxiety disorders predict outcomes during and after cognitive therapy for depression?
Vittengl JR; Clark LA; Smits JAJ; Thase ME; Jarrett RB
J Affect Disord; 2019 Jan; 242():150-158. PubMed ID: 30176494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
